Natera, Inc.

NasdaqGS:NTRA Aktierapport

Börsvärde: US$26.7b

Natera Framtida tillväxt

Future kriterier kontrolleras 4/6

Natera förväntas öka intäkter och intäkter med 62.4% respektive 14.8% per år. EPS förväntas tillväxt med 62.8% per år. Avkastningen på eget kapital förväntas bli 1.6% om 3 år.

Viktig information

62.4%

Tillväxttakt i vinsten

62.83%

Tillväxttakt för EPS

Biotechs vinsttillväxt25.2%
Intäkternas tillväxttakt14.8%
Framtida avkastning på eget kapital1.59%
Bevakning av analytiker

Good

Senast uppdaterad15 May 2026

Senaste uppdateringarna om framtida tillväxt

Analysartikel • May 13

Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report

As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...

Recent updates

Analysartikel • May 13

Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report

As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...
Uppdatering av berättelse • May 05

NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory

Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.
Uppdatering av berättelse • Apr 20

NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook

Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.
Uppdatering av berättelse • Apr 05

NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook

Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.
Uppdatering av berättelse • Mar 22

NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook

The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.
Seeking Alpha • Mar 17

Natera Looks Compelling As Oncology Testing Momentum Keeps Building

Summary NTRA’s oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA’s 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio. Their Foresight acquisition also strengthens NTRA’s MRD moat through PhasED-Seq technology, better testing sensitivity, and taps into lymphoma screening. I reckon NTRA’s valuation multiples are expensive. However, I think their current growth rate with Signatera justifies its price tag, which is why I lean bullish. Read the full article on Seeking Alpha
Uppdatering av berättelse • Mar 07

NTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside

The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.
Uppdatering av berättelse • Feb 21

NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory

Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.
Uppdatering av berättelse • Feb 07

NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook

Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.
Uppdatering av berättelse • Jan 24

NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory

Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.
Uppdatering av berättelse • Jan 09

NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory

Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.
Uppdatering av berättelse • Dec 26

NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory

The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.
Uppdatering av berättelse • Dec 12

NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns

Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.
Uppdatering av berättelse • Nov 27

NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook

Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.
Uppdatering av berättelse • Nov 11

NTRA: Recent Clinical Results And Cash Flow Risks Will Shape Future Performance

Natera's analyst price target has increased significantly from $202.50 to $222.58. This reflects analysts' optimism following raised estimates and expectations for continued growth, in light of recent positive clinical trial updates and industry leadership.
Uppdatering av berättelse • Oct 27

Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets

Analysts raised their fair value estimate for Natera to $202.50 from $193.80. They cited momentum from recent clinical developments, positive trial updates, and ongoing strength in the company’s diagnostic and oncology business lines.
Uppdatering av berättelse • Sep 28

Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities

Analysts lowered Natera’s price target modestly to $193.80 as continued optimism around its liquid biopsy leadership and growth opportunities was tempered by renewed concerns about elevated valuation and margin outlook. Analyst Commentary Bullish analysts note Natera's leadership in liquid biopsy testing and large addressable markets in prenatal, minimal residual disease, and potential cancer screening, supporting long-term double-digit revenue growth.
Uppdatering av berättelse • Sep 04

Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities

Analysts raised Natera’s price target slightly to $198.45, citing strong Q2 results, continued leadership in liquid biopsy, robust pipeline momentum, and increasing market opportunities in cancer screening and prenatal testing. Analyst Commentary Bullish analysts cited Natera's solid Q2 beat, with significant revenue upside and sustained business momentum, leading to raised outlooks for 2025.
Analysartikel • Aug 31

Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking

Natera, Inc. ( NASDAQ:NTRA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...
Analysartikel • May 18

There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price

Natera, Inc.'s ( NASDAQ:NTRA ) price-to-sales (or "P/S") ratio of 11.4x might make it look like a sell right now...
User avatar
Ny berättelse • May 11

Signatera, Prospera And Renasight Will Transform Diagnostics

Strong revenue growth driven by increased diagnostic volumes and strategic partnerships positively impacts Natera's earnings and future revenue potential.

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:NTRA - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/20283,95519025573913
12/31/20273,296-4416646918
12/31/20262,791-21911526218
3/31/20262,501-22672211N/A
12/31/20252,306-20876215N/A
9/30/20252,117-30994194N/A
6/30/20251,964-253105187N/A
3/31/20251,831-19085153N/A
12/31/20241,697-19059136N/A
9/30/20241,532-215-4425N/A
6/30/20241,361-292-118-56N/A
3/31/20241,209-365-197-139N/A
12/31/20231,083-435-286-247N/A
9/30/2023989-499-311-270N/A
6/30/2023931-512-387-343N/A
3/31/2023868-546-419-375N/A
12/31/2022820-548-479-432N/A
9/30/2022776-546-498-449N/A
6/30/2022723-576-492-438N/A
3/31/2022667-546-453-398N/A
12/31/2021625-472-385-335N/A
9/30/2021565-408-354-310N/A
6/30/2021505-315-280-252N/A
3/31/2021449-258-244-222N/A
12/31/2020391-230-202-183N/A
9/30/2020362-189-139-124N/A
6/30/2020342-153-117-104N/A
3/31/2020330-126-79-67N/A
12/31/2019302-125N/A-63N/A
9/30/2019286-121N/A-61N/A
6/30/2019273-128N/A-72N/A
3/31/2019262-129N/A-103N/A
12/31/2018258-128N/A-71N/A
9/30/2018243-144N/A-86N/A
6/30/2018233-142N/A-94N/A
3/31/2018223-137N/A-72N/A
12/31/2017210-138N/A-98N/A
9/30/2017207-128N/A-99N/A
6/30/2017205-126N/A-92N/A
3/31/2017205-121N/A-99N/A
12/31/2016213-100N/A-74N/A
9/30/2016221-81N/A-49N/A
6/30/2016212-72N/A-42N/A
3/31/2016205-69N/A-35N/A
12/31/2015190-70N/A-38N/A
9/30/2015187-46N/A-23N/A
6/30/2015189-28N/A0N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: NTRA förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.5% ).

Resultat vs marknad: NTRA förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.

Höga tillväxtresultat: NTRA förväntas bli lönsam under de kommande 3 åren.

Intäkt vs marknad: NTRA s intäkter ( 14.8% per år) förväntas växa snabbare än US marknaden ( 11.7% per år).

Hög tillväxtintäkter: NTRA s intäkter ( 14.8% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: NTRA s avkastning på eget kapital förväntas bli låg om 3 år ( 1.6 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/18 09:04
Aktiekurs vid dagens slut2026/05/15 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Natera, Inc. bevakas av 30 analytiker. 18 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Raymond MyersBenchmark Company